- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05590325
Pharmacokinetics and Safety of DolutegravIr in Neonate (PETITE-DTG)
Open Label, Single Arm, Two-stage Trial to Evaluate the Single and Multi-dose Pharmacokinetics and Safety of the Paediatric Dolutegravir (10 mg, Scored) Dispersible Tablet in HIV-exposed Neonates
Study Overview
Detailed Description
A Phase I/II, open-label, single arm, two-stage trial to evaluate the single and multi-dose PK and safety of DTG in HIV-exposed neonates on ARV prophylaxis. HIV-exposed term neonates born mothers with HIV on DTG-based antiretroviral therapy with a birth weight ≥2000 g who are on ARV postnatal prophylaxis will be enrolled.
Enrolment will be in two stages:
- Stage 1 will assess a single 5 mg dose of the DTG-DT in two sequential cohorts: Cohort 1A (n=8) and Cohort 1B (n=8).
- Stage 2 will assess multiple 5 mg doses of the DTG-DT and DTG-ODF in two parallel cohorts: Cohort 2A (n=20) and Cohort 2B (n=20).
Per national guidelines, all infants receive a birth HIV nucleic acid test (NAT). HIV NAT test results for the infant may or may not be available (HIV pending) at the time of study entry. HIV NAT results are typically available within 72 hours of the blood sample being taken and are checked and acted upon by the hospital HIV PMTCT service, as part of standard of care. If an HIV NAT result comes back positive whilst the neonate is on study, the neonate will not receive any further DTG doses, revert to standard of care antiretroviral therapy (ART), and be followed for safety for the duration of the study.
Primary Objectives:
- To evaluate the pharmacokinetics of dolutegravir (DTG) during the first 28 days of life in HIV-exposed term neonates (born to a mother with HIV) following administration of DTG dispersible tablet (DTG-DT) and DTG oral dispersible film (DTG-ODF)
- To determine the safety of DTG during the first 28 days of life in HIV-exposed term neonates following administration of DTG-DT and DTG-ODF
Secondary Objectives:
• To quantitatively and qualitatively assess the acceptability of DTG-DT and DTG-ODF for the neonate, the caregiver and health workers
Primary endpoints:
- DTG plasma pharmacokinetics parameters: area under the concentration time curve (AUC); maximum plasma concentration (Cmax), apparent clearance (CL/F), and trough concentration (Ctrough)
- Occurrence of the following events: adverse events of Grade 3 or higher; treatment-related adverse events of Grade 3 or higher; any adverse events
Secondary endpoints:
• Acceptability to caregivers and neonates of using DTG-DT will be measured by means of a questionnaire
Study Type
Enrollment (Estimated)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Contact
- Name: Adrie Bekker, Prof
- Phone Number: +27 (0)219389198
- Email: adrie@sun.ac.za
Study Contact Backup
- Name: Tina Sachs, MSc
- Phone Number: +27 (0)620474701
- Email: tsachs@sun.ca.za
Study Locations
-
-
Western Cape
-
Cape Town, Western Cape, South Africa, 7505
- Recruiting
- Tygerberg Hospital
-
Contact:
- Adrie Beker, Prof
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
Stage 1: Inclusion Criteria
- HIV-exposed neonate (pending HIV status) born to a woman within HIV on DTG-based ART
- Birth weight of ≥2000 g and on standard of care ARV prophylaxis
Cohort Specific Inclusion Criteria in Stage 1 must be met at Study Entry:
Cohort 1A: Infant <14 days of life Cohort 1B: Infant ≤3 days of life
Stage 2: Inclusion Criteria
Low risk* HIV-exposed neonate (pending HIV status) born to a virologically suppressed woman on DTG-based ART
*Neonate born to a woman with a documented plasma HIV-1 RNA result <50 copies/mL in the 4 weeks prior to delivery or between delivery and infant study entry
- Birth weight of ≥2000 g and on standard of care ARV prophylaxis
Cohort Specific Inclusion Criteria in Stage 2 must be met at Study Entry:
Cohort 2: Infant <7 days of life
Exclusion Criteria:
• Less than 37 weeks gestational age at birth
- Known blood group incompatibilities which can result in hemolytic disease of the newborn (e.g., Rh-negative mother, presence of antibodies on neonatal red blood cells, etc.)
- Total bilirubin values approaching an exchange transfusion as defined by local guidelines (Section 18.2)
- Haemoglobin value of <13.0 g/dL
- Platelet count of less than 50,000 cells/mm3)
- Decreased total white blood cell count (Grade 3 and above)
- Creatinine value more than 1.3 the upper limit of normal (ULN) for gestational age and postnatal age (Grade 2 and above)
- AST or ALT of more than 2.5 the ULN (Grade 2 and above)
- Any other current Grade ≥3 event on the DAIDS toxicity table
- Severe congenital abnormalities or critically ill neonates at discretion of the examining clinician
- Receiving medicine(s) that can impact DTG pharmacokinetics (Section 8.7)
- Participation in another clinical trial
- HIV-infected neonates
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: single arm, two-stage
Participants will be enrolled in two stages:
|
Single dose of the DTG-DT in two sequential cohorts and multiple-doses of the DTG-DT or DTG-ODF in a two cohorts. Qualitative Acceptability will be collected from mothers and health workers in structured discussion guides. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
In Cohort 1, PK analysis will be performed to calculate the following parameter: Cmax
Time Frame: first 28 days of life
|
Cmax will be taken directly from the observed concentration-time data.
|
first 28 days of life
|
In Cohort 1, PK analysis will be performed to calculate the following parameter: Clast,
Time Frame: first 28 days of life
|
Clast will be taken directly from the observed concentration-time data.
|
first 28 days of life
|
In Cohort 1, PK analysis will be performed to calculate the following parameter: Tmax
Time Frame: first 28 days of life
|
Tmax will be taken directly from the observed concentration-time data.
|
first 28 days of life
|
In Cohort 1, PK analysis will be performed to calculate the following parameter: C24
Time Frame: first 28 days of life
|
C24 will be taken directly from the observed concentration-time data.
|
first 28 days of life
|
In Cohort 1, PK analysis will be performed to calculate the following parameter: AUC0-24
Time Frame: first 28 days of life
|
AUC0-all will be determined using the linear-up log-down trapezoidal method.
Total body clearance for extravascular administration will be calculated using Dose/ AUC0-infinity.
Median (range), means (standard deviations), and geometric means with 95%CI for each PK parameter will be calculated separately for Cohorts 1A and 1B, as well as for Cohort 1A/1B together.
|
first 28 days of life
|
In Cohort 1, PK analysis will be performed to calculate the following parameter: AUC0-infinity
Time Frame: first 28 days of life
|
AUC0-infinity will be determined using the linear-up log-down trapezoidal method.
Total body clearance for extravascular administration will be calculated using Dose/ AUC0-infinity.
Median (range), means (standard deviations), and geometric means with 95%CI for each PK parameter will be calculated separately for Cohorts 1A and 1B, as well as for Cohort 1A/1B together.
|
first 28 days of life
|
In Cohort 1, PK analysis will be performed to calculate the following parameter: Ratio AUC0-24 / AUC0-infinity
Time Frame: first 28 days of life
|
Ratio AUC0-24 / AUC0-infinity will be determined using the linear-up log-down trapezoidal method.
Total body clearance for extravascular administration will be calculated using Dose/ AUC0-infinity.
Median (range), means (standard deviations), and geometric means with 95%CI for each PK parameter will be calculated separately for Cohorts 1A and 1B, as well as for Cohort 1A/1B together.concentration-time
data.
|
first 28 days of life
|
Reporting adverse events of Grade 3 or higher; treatment-related adverse events of Grade 3 or higher; any adverse events neonates following administration of DTG dispersible tablet
Time Frame: first 28 days of life
|
Using the DAIDS toxicity table and protocol specific safety criteria
|
first 28 days of life
|
In Cohorts 2A and 2B, both non-compartmental and population PK analyses will be performed using the following parameter: Cmax
Time Frame: first 28 days of life
|
Population means and variances of Cmax for DTG will be estimated using nonlinear mixed-effects regression models.
Subject covariates will be assessed to explain sources of inter-subject PK variability.
|
first 28 days of life
|
In Cohorts 2A and 2B, both non-compartmental and population PK analyses will be performed using the following parameter: AUC0-tau
Time Frame: first 28 days of life
|
Population means and variances of AUC0-tau for DTG will be estimated using nonlinear mixed-effects regression models.
Subject covariates will be assessed to explain sources of inter-subject PK variability.
Changes in DTG drug exposures in neonates following multi-doses of DTG-DT and DTG-ODF during the first 28 days of life will be estimated using the final model.
|
first 28 days of life
|
In Cohorts 2A and 2B, both non-compartmental and population PK analyses will be performed using the following parameter: CTau
Time Frame: first 28 days of life
|
Population means and variances of CTau for DTG will be estimated using nonlinear mixed-effects regression models.
Subject covariates will be assessed to explain sources of inter-subject PK variability.
Changes in DTG trough concentrations in neonates following multi-doses of DTG-DT and DTG-ODF during the first 28 days of life will be estimated using the final model.
|
first 28 days of life
|
In Cohorts 2A and 2B, both non-compartmental and population PK analyses will be performed using the following parameter: Tmax
Time Frame: first 28 days of life
|
Population means and variances of Tmax for DTG will be estimated using nonlinear mixed-effects regression models.
Subject covariates will be assessed to explain sources of inter-subject PK variability.
|
first 28 days of life
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Acceptability to caregivers and neonates of using DTG-DT will be measured by means of a questionnaire
Time Frame: first 28 days of life
|
key characteristics: Palatability, Swallowability, the device used to administer the dose, The complexity for the caregiver to prepare the dose correctly, Required dose, Need for a vehicle, Dosing frequency and duration of treatment, Selected administration devices, Primary container closure system, Actual mode of administration that reflects understanding of user instructions and feasibility of following them, Acceptability will be recorded by focusing on: Attitude of the child when presented with the formulation: facial expression, crying or smiling, reaction to drug intake, fighting drug intake, spitting out the suspension, Swallowability, i.e., ability to take the full dose, The way the caregiver prepares the dose |
first 28 days of life
|
Qualitative acceptability data from mothers and health workers
Time Frame: first 28 days of life
|
Data will be collected using a semi-structured discussion guide
|
first 28 days of life
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Adrie Bekker, Prof, University of Stellenbosch
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2019-36-SUN-MDR
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hiv
-
University of Alabama at BirminghamMobile County Health Deparment; Alabama Department of Public HealthRecruitingHIV | HIV Testing | HIV Linkage to Care | HIV TreatmentUnited States
-
ANRS, Emerging Infectious DiseasesHopital Universitaire Robert-Debre; Institut de Recherche pour le Developpement and other collaboratorsUnknownHIV | HIV-uninfected Children | Children Exposed to HIVCameroon
-
French National Agency for Research on AIDS and...Elizabeth Glaser Pediatric AIDS FoundationCompletedPartner HIV Testing | Couple HIV Counseling | Couple Communication | HIV IncidenceCameroon, Dominican Republic, Georgia, India
-
University of MinnesotaWithdrawnHIV Infections | HIV/AIDS | Hiv | AIDS | Aids/Hiv Problem | AIDS and InfectionsUnited States
-
CDC FoundationGilead SciencesUnknownHIV Preexposure Prophylaxis | HIV ChemoprophylaxisUnited States
-
Africa Health Research InstituteLondon School of Hygiene and Tropical Medicine; University College, London; University... and other collaboratorsRecruiting
-
Massachusetts General HospitalNational Institute of Mental Health (NIMH); Fenway Community Health; Tuberculosis...CompletedHIV/STI Risk | HIV/STI IncidenceUnited States, India
-
Erasmus Medical CenterNot yet recruitingHIV Infections | Hiv | HIV-1-infection | HIV I InfectionNetherlands
-
Hospital Clinic of BarcelonaCompletedIntegrase Inhibitors, HIV; HIV PROTEASE INHIBSpain
-
University of WashingtonNational Institute of Mental Health (NIMH)RecruitingHIV Prevention | HIV Preexposure Prophylaxis | ImplementationKenya
Clinical Trials on Dolutegravir
-
ViiV HealthcareGlaxoSmithKlineCompletedHIV InfectionsUnited States
-
ViiV HealthcareCompleted
-
University of KwaZuluCentre for the AIDS Programme of Research in South AfricaRecruitingTuberculosis | HivSouth Africa
-
ViiV HealthcareGlaxoSmithKlineCompletedInfection, Human Immunodeficiency VirusUnited States
-
ViiV HealthcareGlaxoSmithKline; ShionogiCompletedInfections, Human Immunodeficiency Virus and HerpesviridaeUnited States
-
ViiV HealthcareGlaxoSmithKline; ShionogiCompleted
-
National Institute of Allergy and Infectious Diseases...Eunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsRecruitingHIVUnited States, Brazil, Puerto Rico, South Africa, Thailand
-
Fundación HuéspedViiV HealthcareCompletedHIV-1 InfectionArgentina
-
Thomas BenfieldRecruitingCardiovascular Diseases | HIV Infections | Hiv | Weight Change, Body | HIV Lipodystrophy | HIV CardiomyopathyDenmark
-
ViiV HealthcareGlaxoSmithKlineCompletedInfection, Human Immunodeficiency VirusUnited States